BTIG raised the firm’s price target on Protagonist Therapeutics (PTGX) to $67 from $51 and keeps a Buy rating on the shares. The company’s PN-881 is the only oral IL-17A/F inhibitor, and it achieves potency comparable to bimekizumab in pre-clinical assays, the analyst tells investors in a research note. Eli Lilly’s (LLY) acquisition of Dice in June 2023 for $2.4B for an oral IL-17A inhibitor with only Phase 1 data is seen as a straightforward comp, and PN-881’s “differentiated specificity” could support preferential positioning as the dominant oral IL-17 inhibitor, the firm added.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics selects PN-881 as development candidate
- Protagonist and JNJ say icotrokinra study for PsO meets endpoint
- Protagonist Therapeutics Reports Strong Financial Turnaround
- Wedbush starts Protagonist Therapeutics with an Outperform, $58 target
- Protagonist Therapeutics initiated with an Outperform at Wedbush